Compare AWI & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AWI | RYTM |
|---|---|---|
| Founded | 1860 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 5.8B |
| IPO Year | 1994 | 2017 |
| Metric | AWI | RYTM |
|---|---|---|
| Price | $162.94 | $94.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 18 |
| Target Price | ★ $210.18 | $138.59 |
| AVG Volume (30 Days) | 271.0K | ★ 609.1K |
| Earning Date | 10-27-2026 | 11-03-2026 |
| Dividend Yield | ★ 0.83% | N/A |
| EPS Growth | 17.61 | ★ 28.34 |
| EPS | ★ 3.81 | N/A |
| Revenue | ★ $1,620,800,000.00 | N/A |
| Revenue This Year | $10.24 | $65.10 |
| Revenue Next Year | $7.20 | $78.21 |
| P/E Ratio | $42.70 | ★ N/A |
| Revenue Growth | ★ 12.11 | N/A |
| 52 Week Low | $150.28 | $74.50 |
| 52 Week High | $206.08 | $122.20 |
| Indicator | AWI | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 40.49 | 33.92 |
| Support Level | $159.60 | $82.43 |
| Resistance Level | $162.38 | $99.50 |
| Average True Range (ATR) | 3.50 | 3.51 |
| MACD | 0.28 | -0.16 |
| Stochastic Oscillator | 44.90 | 10.06 |
Armstrong World Industries Inc designs and manufactures exterior architectural applications, including ceilings, specialty walls, and exterior metal solutions, using materials such as mineral fiber, fiberglass, metal, felt, architectural resin and glass, wood, wood fiber, and glass-reinforced-gypsum. Its segments include Mineral Fiber, which produces suspended mineral fiber and fiberglass ceiling systems and includes results from the Worthington Armstrong Venture (WAVE) for ceiling suspension system (grid) products; Architectural Specialties, which designs, produces, and sources specialty ceilings, walls, and other architectural applications for commercial settings, with revenues mainly project driven; and Unallocated Corporate. The company operates in the United States and Canada.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.